Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• In a network meta-analysis comparing the effectiveness of lanadelumab and berotralstat for preventing hereditary angioedema (HAE) attacks, lanadelumab (300 mg every 2 or 4 weeks) was found to be statistically more effective than berotralstat (150 mg and 110 mg once daily) in reducing HAE attack rates and achieving a ≥90% reduction in monthly attacks.
• A systematic review involving 15 studies with 912 participants showed that berotralstat, C1-Inhibitor (INH), and lanadelumab were effective in reducing the number of HAE attacks and improving quality of life. However, lanadelumab and C1-INH were specifically noted for reducing the severity of breakthrough attacks, which was not reported for berotralstat.
• No increase in adverse events, including serious adverse events, was reported for berotralstat, avoralstat, C1-INH (all forms), and lanadelumab compared with placebo in the systematic review of 15 studies involving 912 participants.
• Mortality was not reported in any of the included studies, and specific data on serious adverse events were not available for danazol, preventing any conclusions regarding its safety.
• Studies primarily included populations with Type I and II hereditary angioedema (HAE), confirming the effectiveness of berotralstat, C1-INH, danazol, and lanadelumab in reducing HAE attacks. No data were available for Type III HAE, limiting conclusions for this subgroup.